Greece Pharmaceuticals & Healthcare Q3 2019
In Greece, multinational pharmaceutical firms will continue to face considerable challenges. The healthcare system as awhole will continue to struggle due to a lack of funding, resulting in high levels of debt. Medicine sales will remain on a low growthtrajectory, albeit now positive, due to restrictive public funding. Repressive government policy, including aggressive pricing, highclawback and rebates, will continue to repress opportunities and create a high degree of risk. This will be exacerbated by theimplementation of the new health technology assessment medicine reimbursement scheme.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook